HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CRN president

This article was originally published in The Tan Sheet

Executive Summary

Annette Dickinson, PhD, named president of trade association following Feb. 27 board vote. Dickinson took the helm as acting president in January upon expiration of John Cordaro's contract (1"The Tan Sheet" Jan. 6, 2003, p. 13). Although the board considered initiating an outside search to fill the top spot, Dickinson prevailed due in part to her 29 years with the group. "She possesses an ideal combination of scientific knowledge and regulatory know-how" and has "attained high marks from industry executives as well as from legislators and the regulatory and scientific communities," said board Chairman Byron Johnson, Access Business Group/Nutrilite. Dickinson will help solidify CRN's strong foundation in science as it looks to revitalize the supplement industry (2"The Tan Sheet" Oct. 14, 2002, p. 10)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS129552

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel